Αποτελέσματα αναζήτησης - "хроническая сердечная недостаточность с сохраненной фракцией выброса"

Πηγή: Zaporozhye мedical journal; Vol. 23 No. 1 (2021); 24-31 ; Запорожский медицинский журнал; Том 23 № 1 (2021); 24-31 ; Запорізький медичний журнал; Том 23 № 1 (2021); 24-31 ; 2310-1210 ; 2306-4145

Θεματικοί όροι: хроническая сердечная недостаточность с сохраненной фракцией выброса левого желудочка, пентоксифиллин, диастолическая дисфункция, качество жизни, пожилой возраст, chronic heart failure with preserved left ventricular ejection fraction, pentoxifylline, diastolic dysfunction, quality of life, aged, хронічна серцева недостатність зі збереженою фракцією викиду лівого шлуночка, пентоксифілін, діастолічна дисфункція, якість життя, похилий вік

Περιγραφή αρχείου: application/pdf

Relation: http://zmj.zsmu.edu.ua/article/view/224839/225164; http://zmj.zsmu.edu.ua/article/view/224839

Διαθεσιμότητα: http://zmj.zsmu.edu.ua/article/view/224839

View record from BASE

6

Academic Journal

New score scale for assessing the risk of establishing chronic heart failure with preserved ejection fraction ; Новая балльная шкала оценки риска установления хронической сердечной недостаточности с сохраненной фракцией выброса

Συγγραφείς: O. M. Zherko, E. I. Shkrebneva, О. М. Жерко, Э. И. Шкребнева

Πηγή: Medical Visualization; Том 25, № 3 (2021); 83-96 ; Медицинская визуализация; Том 25, № 3 (2021); 83-96 ; 2408-9516 ; 1607-0763

Θεματικοί όροι: балльная шкала, 2D Speckle Tracking echocardiography, chronic heart failure with preserved ejection fraction, score scale, 2D Speckle Tracking эхокардиография, хроническая сердечная недостаточность с сохраненной фракцией выброса

Περιγραφή αρχείου: application/pdf

Relation: https://medvis.vidar.ru/jour/article/view/939/674; https://medvis.vidar.ru/jour/article/downloadSuppFile/939/969; https://medvis.vidar.ru/jour/article/downloadSuppFile/939/970; https://medvis.vidar.ru/jour/article/downloadSuppFile/939/971; https://medvis.vidar.ru/jour/article/downloadSuppFile/939/972; https://medvis.vidar.ru/jour/article/downloadSuppFile/939/973; https://medvis.vidar.ru/jour/article/downloadSuppFile/939/974; https://medvis.vidar.ru/jour/article/downloadSuppFile/939/975; Pieske B., Tschöpe C., de Boer R.A., Fraser A.G., Anker S.D., Donal E., Edelmann F., Fu M., Guazzi M., Lam C.S.P., Lancellotti P., Melenovsky V., Morris D.A., Nagel E., Pieske-Kraigher E., Ponikowski P., Solomon S.D., Vasan R.S., Rutten F.H., Voors A.A., Ruschitzka F., Paulus W.J., Seferovic P., Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFAPEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur. Heart J. 2019; 40 (40): 3297–3317. http://doi.org/10.1093/eurheartj/ehz641.; Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S., Falk V., González-Juanatey J.R., Harjola V.P., Jankowska E.A., Jessup M., Linde C., Nihoyannopoulos P., Parissis J.T., Pieske B., Riley J.P., Rosano G.M.C., Ruilope L.M., Ruschitzka F., Rutten F.H., van der Meer P.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016; 37 (27): 21292200. https://doi.org/10.1093/eurheartj/ehw128; Lourenço A.P., Leite-Moreira A.F., Balligand J.L., Bauersachs J., Dawson D., de Boer R.A., de Windt L.J., Falcão-Pires I., Fontes-Carvalho R., Franz S., Giacca M., Hilfiker-Kleiner D., Hirsch E., Maack C., Mayr M., Pieske B., Thum T., Tocchetti C.G., Brutsaert D.L., Heymans S. An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur. J. Heart Fail. 2018; 20 (2): 216–227. http://doi.org/10.1002/ejhf.1059; Сердечная недостаточность / Под общей ред. Ю.П. Островского. Минск: Беларуская навука, 2016. 503 с.; Patel A.R., Blair J.A. Heart Failure With Preserved Ejection Fraction Have We Finally Found the Perfect Noninvasive Biomarker? Circulation: Cardiovascular Imaging. 2016; 9: e005905. https://doi.org/10.1161/CIRCIMAGING.116.005905; Gupta D.K. Heart Failure With Preserved Ejection Fraction: An Opportunity for Reflection. J. Am. Heart Assoc. 2017; 6 (2): e005595. http://doi.org/10.1161/JAHA.117.005595; Tobushi T., Nakano M., Hosokawa K., Koga H., Yamada A. Improved Diastolic Function Is Associated With Higher Cardiac Output in Patients With Heart Failure Irrespective of Left Ventricular Ejection Fraction. J. Am. Heart Assoc. 2017; 6: e003389. http://doi.org/10.1161/JAHA.116.003389; Shah A.M., Claggett B., Sweitzer N.K., Shah S.J., Anand I.S., Liu L., Pitt B., Pfeffer M.A., Solomon S.D. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circulation. 2015; 132: 402–414.; Garbi M., Edvardsen T., Bax J., Petersen S.E., McDonagh T., Filippatos G., Lancellotti P. EACVI appropriateness criteria for the use of cardiovascular imaging in heart failure derived from European National Imaging Societies voting. Eur. Heart J. – Cardiovasc. Imaging. 2016; 17: 711–721. https://doi.org/10.1093/ehjci/jew081; Douglas P.S., Carabello B.A., Lang R.M., Lopez L., Pellikka P.A., Picard M.H., Thomas J.D., Varghese P., Wang T.Y., Weissman N.J., Wilgus R. 2019 ACC/AHA/ASE Key Data Elements and Definitions for Transthoracic Echocardiography: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Transthoracic Echocardiography) and the American Society of Echocardiography. Circulation: Cardiovascular Imaging. 2019; 12: e000027. https://doi.org/10.1161/HCI.0000000000000027; Paulus W.J., Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflmmation. J. Am. Coll. Cardiol. 2013; 62: 263–271.; Жерко О.М. Клиническая трансторакальная эхокардиография. Минск: Альфакнига, 2016. 832 с.; Otto C. The practice of clinical echocardiography. 5nd ed. Philadelphia, Pennsylvania: Elsevier, 2017. 965 р.; Nagueh S.F., Smiseth O.A., Appleton C.P., Byrd B.F. 3rd, Dokainish H., Edvardsen T., Flachskampf F.A., Gillebert T.C., Klein A.L., Lancellotti P., Marino P., Oh J.K., Popescu B.A., Waggoner A.D. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiography. 2016; 29: 277–314. https://doi.org/10.1016/j.echo.2016.01.011; Galiè N., Humbert M., Vachiery J.L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Vonk Noordegraaf A., Beghetti M., Ghofrani A., Gomez Sanchez M.A., Hansmann G., Klepetko W., Lancellotti P., Matucci M., McDonagh T., Pierard L., Trindade P.T., Zompatori M., Hoeper M.; ESC Scientific Document Group. 2015 ESC/ ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur. Heart J. 2016; 37: 67–119. https://doi.org/10.1093/eurheartj/ehv317; Reddy Y.N.V., Carter R.E., Obokata M., Redfield M.M., Borlaug B.A. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018; 138: 861–870. https://doi.org/10.1161/CIRCULATIONAHA.118.034646; Flachskampf F.A., Biering-Sørensen T., Solomon S.D., Duvernoy O., Bjerner T., Smiseth O.A. Cardiac Imaging to Evaluate Left Ventricular Diastolic Function. JACC: Cardiovascular Imaging. 2015; 8 (9): 1071–1093. https://doi.org/10.1016/j.jcmg.2015.07.004; Kasner M., Westermann D., Lopez B., Gaub R., Escher F., Kühl U., Schultheiss H.P., Tschöpe C. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J. Am. Coll. Cardiol. 2011; 57: 977–985. http://doi.org/10.1016/j.jacc.2010.10.024; Dokainish H., Nguyen J.S., Sengupta R., Pillai M., Alam M., Bobek J., Lakkis N. Do additional echocardiographic variables increase the accuracy of E/e’ for predicting left ventricular filing pressure in normal ejection fraction? An echocardiographic and invasive hemodynamic study. J. Am. Soc. Echocardiogr. 2010; 23: 156–161. http://doi.org/10.1016/j.echo.2009.11.015; Collier P.A., Phelan D., Klein A.A. Test in Context: Myocardial Strain Measured by Speckle-Tracking Echocardiography. J. Am. Coll. Cardiol. 2017; 69: 10431056. http://doi.org/10.1016/j.jacc.2016.12.012; Vecera J., Penicka M., Eriksen M., Russell K., Bartunek J., Vanderheyden M., Smiseth O.A. Wasted septal work in left ventricular dyssynchrony: a novel principle to predict response to cardiac resynchronization therapy. Eur. Heart J. – Cardiovasc. Imaging. 2016; 17: 624–632. http://doi.org/10.1093/ehjci/jew019; Čelutkienė J., Plymen C.M., Flachskampf F.A., de Boer R.A., Grapsa J., Manka R., Anderson L., Garbi M., Barberis V., Filardi P.P., Gargiulo P., Zamorano J.L., Lainscak M., Seferovic P., Ruschitzka F., Rosano G.M.C., Nihoyannopoulos P. Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. EJHF. 2018; 20: 1615–1633. http://doi.org/10.1002/ejhf.1330; https://medvis.vidar.ru/jour/article/view/939

Διαθεσιμότητα: https://medvis.vidar.ru/jour/article/view/939
https://doi.org/10.24835/1607-0763-939

View record from BASE

7

Academic Journal

Atrial Fibrillation and Heart Failure as the Onset of AL-Amyloidosis ; Фибрилляция предсердий и сердечная недостаточность в дебюте Al-амилоидоза

Συγγραφείς: E. V. Reznik, V. A. Lazarev, S. V. Borisovskay, G. N. Golukhov, Е. В. Резник, В. А. Лазарев, С. В. Борисовская, Г. Н. Голухов

Πηγή: The Russian Archives of Internal Medicine; Том 11, № 6 (2021); 457-465 ; Архивъ внутренней медицины; Том 11, № 6 (2021); 457-465 ; 2411-6564 ; 2226-6704

Θεματικοί όροι: кардиоренальный синдром, amyloid cardiomyopathy, chronic heart failure with preserved ejection fraction, atrial fibrillation, left ventricular hypertrophy, chronic kidney disease, proteinuria, nephrotic syndrome, cardiorenal syndrome, амилоидная кардиомиопатия, хроническая сердечная недостаточность с сохраненной фракцией выброса левого желудочка, фибрилляция предсердий, гипертрофия левого желудочка, хроническая болезнь почек, протеинурия, нефротический синдром

Περιγραφή αρχείου: application/pdf

Relation: https://www.medarhive.ru/jour/article/view/1337/1071; https://www.medarhive.ru/jour/article/view/1337/1079; https://www.medarhive.ru/jour/article/view/1337/1083; Rysava R. AL amyloidosis: advances in diagnostics and treatment. Nephrol Dial Transplant. 2019; 34(9): 1460-6. doi:10.1093/ndt/gfy291. PubMed PMID: 30299492.; Kristen AV, Perz JB, Schonland SO et al. Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J Heart Lung Transplant. 2007; 26(12): 1313-9. doi:10.1016/j.healun.2007.09.014. PubMed PMID: 18096484.; Dubrey SW, Cha K, Anderson J et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998; 91(2): 141-57. doi:10.1093/qjmed/91.2.141. PubMed PMID: 9578896.; Karafiatova L, Pika T. Amyloid cardiomyopathy. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2017; 161(2): 117-27. doi:10.5507/bp.2017.001. PubMed PMID: 28145535.; Резник Е.В., Нгуен Т.Л., Степанова Е.А. и др. Амилоидоз сердца: взгляд терапевта и кардиолога. Архивъ внутренней медицины. 2020; 10(6): 430-457. https://doi.org/10.20514/2226-6704-2020-10-6-430-457; Лысенко () Л.В., Рамеев В.В., Моисеев С.В. и др. Клинические рекомендации по диагностике и лечению системного амилоидоза. Клин фармакол тер. 2020; 29(1): 13-24; Резник Е.В., Степанова E.A., Нгуен Т. и др. Ретроспективный анализ поражения сердечно-сосудистой системы у пациентов системным амилоидозом. Кардиоваскулярная терапия и профилактика. 2021; 20(1): 2496. Reznik E.V., Stepanova E.A., Nguyen T. et al. Retrospective analysis of cardiovascular involvement in patients with systemic amyloidosis. Cardiovascular Therapy and Prevention. 2021; 20(1): 2496. [In Russian]; Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016; 68(12): 1323-41. doi:10.1016/j.jacc.2016.06.053. PubMed PMID: 27634125.; Резник Е.В., Никитин И.Г. Кардиоренальный синдром у пациентов с сердечной недостаточностью как этап кардиоренального континуума (часть 2): прогностическое значение, профилактика и лечение. Архивъ внутренней медицины. 2019; 9(2): 93-106. doi:10.20514/2226-6704-2019-9-2-93-106; Резник Е.В., Никитин И.Г. Кардиоренальный синдром у пациентов с сердечной недостаточностью как этап кардиоренального континуума (часть I): определение, классификация, патогенез, диагностика, эпидемиология (обзор литературы). Архивъ внутренней медицины. 2019; 9(1): 5-22. doi:10.20514/2226-6704-2019-9-1-5-22; Wechalekar AD, Gillmore JD, Bird J, et al. Guidelines on the management of AL amyloidosis. British journal of haematology. 2015; 168(2): 186-206. doi:10.1111/bjh.13155. PubMed PMID: 25303672.; Kastritis E, Dimopoulos MA. Recent advances in the management of AL Amyloidosis. British journal of haematology. 2016; 172(2): 170-86. doi:10.1111/bjh.13805. PubMed PMID: 26491974.; Fajardo J, Cummings A, Brown E et al. Clinical pathway to screen for cardiac amyloidosis in heart failure with preserved ejection fraction. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2019; 26(sup1): 166-7. doi:10.1080/13506129.2019.1583178. PubMed PMID: 31343333.; https://www.medarhive.ru/jour/article/view/1337

Διαθεσιμότητα: https://www.medarhive.ru/jour/article/view/1337
https://doi.org/10.20514/2226-6704-2021-11-6-457-465

View record from BASE

8

Academic Journal

Predictors of an adverse course of heart failure with preserved left ventricular ejection fraction in patients with obstructive sleep apnea syndrome

Συγγραφείς: A. T. Teplyakov, A. V. Yakovlev, S. N. Shilov, N. F. Yakovleva, E. N. Berezikova, E. V. Grakova, K. V. Kopeva, S. D. Mayanskaya

Πηγή: Бюллетень сибирской медицины, Vol 20, Iss 2, Pp 102-112 (2021)

Θεματικοί όροι: синдром обструктивного апноэ во сне, хроническая сердечная недостаточность с сохраненной фракцией выброса, правожелудочковая дисфункция, легочная гипертензия, Medicine

Relation: https://bulletin.ssmu.ru/jour/article/view/4386; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684; https://doaj.org/article/3b81c85f6cf24bc580a0058a842b67e7

Διαθεσιμότητα: https://doi.org/10.20538/1682-0363-2021-2-102-112
https://doaj.org/article/3b81c85f6cf24bc580a0058a842b67e7

View record from BASE

9

Academic Journal

Pentoxyphylline: possibilities to reduce manifestations of chronic heart failure with preserved left ventricular ejection fraction in elderly

Πηγή: Zaporozhye мedical journal; Vol. 23 No. 1 (2021); 24-31
Запорожский медицинский журнал; Том 23 № 1 (2021); 24-31
Запорізький медичний журнал; Том 23 № 1 (2021); 24-31

Θεματικοί όροι: пожилой возраст, якість життя, хронічна серцева недостатність зі збереженою фракцією викиду лівого шлуночка, пентоксифілін, диастолическая дисфункция, 3. Good health, хроническая сердечная недостаточность с сохраненной фракцией выброса левого желудочка, діастолічна дисфункція, aged, pentoxifylline, пентоксифиллин, quality of life, chronic heart failure with preserved left ventricular ejection fraction, diastolic dysfunction, качество жизни, похилий вік

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://zmj.zsmu.edu.ua/article/view/224839

View record at OpenAIRE Full Text Finder

10

Academic Journal

Cardiac Amyloidosis: Internist and Cardiologist Insight ; Амилоидоз сердца: взгляд терапевта и кардиолога

Συγγραφείς: E. V. Reznik, T. L. Nguyen, E. A. Stepanova, D. V. Ustyuzhanin, I. G. Nikitin, Е. В. Резник, Т. Л. Нгуен, Е. А. Степанова, Д. В. Устюжанин, И. Г. Никитин

Συνεισφορές: The work was carried out within the framework of the state assignment of Russian National Research Medical University n.a. N.I. Pirogov, Ministry of Health of the Russian Federation (R&D state registration number AAAA-A18-118040390145-2), Работа выполнена в рамках государственного задания ФГАОУ ВО РНИМУ им. Н.И. Пирогова МЗ РФ (№ госрегистрации НИР АААА-А18-118040390145-2)

Πηγή: The Russian Archives of Internal Medicine; Том 10, № 6 (2020); 430-457 ; Архивъ внутренней медицины; Том 10, № 6 (2020); 430-457 ; 2411-6564 ; 2226-6704

Θεματικοί όροι: нефротический синдром, amyloid cardiomyopathy, chronic heart failure with preserved ejection fraction, atrial fibrillation, left ventricular hypertrophy, chronic kidney disease, albuminuria, nephrotic syndrome, амилоидная кардиомиопатия, хроническая сердечная недостаточность с сохраненной фракцией выброса левого желудочка, фибрилляция предсердий, гипертрофия левого желудочка, хроническая болезнь почек, альбуминурия

Περιγραφή αρχείου: application/pdf

Relation: https://www.medarhive.ru/jour/article/view/1106/958; https://www.medarhive.ru/jour/article/view/1106/966; Hassan, W., et al., Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management. Tex Heart Inst J, 2005. 32(2): p. 178-84.; Falk, R.H., et al., AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol, 2016. 68(12): p. 1323-41.; Mishra, S., et al., Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol, 2013. 305(1): p. H95-103.; Benson, M.D., et al., Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid, 2018. 25(4): p. 215-219.; Лысенко (Козловская), Л.В., В.В. Рамеев, and С.В. Моисеев, Клинические рекомендации по диагностике и лечению системного амилоидоза. Клиническая фармакология и терапия, 2020. 29(1): p. 13-24. DOI 10.32756/0869-5490-2020-1-13-24; Karafiatova, L. and T. Pika, Amyloid cardiomyopathy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2017. 161(2): p. 117-127.; Fontana, M., et al., Myocardial Amyloidosis: The Exemplar Interstitial Disease. JACC Cardiovasc Imaging, 2019. 12(11 Pt 2): p. 2345-2356.; Pinney, J.H., et al., Systemic amyloidosis in England: an epidemiological study. Br J Haematol, 2013. 161(4): p. 525-32.; Gilstrap, L.G., et al., Epidemiology of Cardiac AmyloidosisAssociated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. Circ Heart Fail, 2019. 12(6): p. e005407.; Резник, Е.В., et al., Хроническая сердечная недостаточность у больных с системным амилоидозом. Кардиоваскулярная терапия и профилактика. in press.; Desport, E., et al., Al amyloidosis. Orphanet J Rare Dis, 2012. 7: p. 54.; Bird, J., et al., UK Myeloma Forum (U KMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation o f newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol, 2009. 147(1): p. 22-42.; Kastritis, E. and M.A. Dimopoulos, Recent advances in the management of AL Amyloidosis. Br J Haematol, 2016. 172(2) : p. 170-86.; Quarta, C.C., et al., The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med, 2015. 372(1): p. 21-9.; Maurer, M.S., et al., Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amy loidosis. Circ Heart Fail, 2019. 12(9): p. e006075.; Gillmore, J.D., et al., Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol, 2015. 168(2 ): p. 207-18.; Donnelly, J.P. and M. Hanna, Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med, 2017. 84( 12 Suppl 3): p. 12-26.; Hou, X., M.I. Aguilar, and D.H. Small, Transthyretin and familial amyloidotic polyneuropathy. Recent progress in un derstanding the molecular mechanism of neurodegeneration. FEBS J, 2007. 274(7): p. 1637-50.; Sekijima, Y., J.W. Kelly, and S. Ikeda, Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des, 2008. 14(30): p. 3219-30.; Gonzalez-Lopez, E., et al., Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J, 2015. 36(38): p. 2585-94.; Seferovic, P.M., et al., Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and p atient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail, 2019.; Damy, T., et al., Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J, 2016. 37(23): p. 1826-34.; Galat, A., et al., Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur Heart J, 2016 . 37(47): p. 3525-3531.; Castano, A., et al., Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with sev ere aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J, 2017. 38(38): p. 2879-2887.; Lopez-Sainz, A., et al., Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or co nduction disorders. Amyloid, 2019. 26(3): p. 156-163.; Гудкова, А.Я., Е.Н. Семернин, and А.А. Полякова, Спектр мутаций в гене транстиретина в когорте пациентов с хроничес кой сердечной недостаточностью. Трансляционная Медицина, 2016. 3(1): p. 34-38. https://doi.org/10.18705/2311-4495-2016-3-1-34-38.; Johnson, S.M., et al., The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol, 2012. 421(2-3): p. 185-203.; Ando, Y., et al., Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis, 2013. 8: p. 31.; Rapezzi, C., et al., Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively ca rdiac phenotype: an Italian perspective. Eur Heart J, 2013. 34(7): p. 520-8.; Sekijima, Y., et al., The current status of the Tran sthyretin Amyloidosis Outcomes Survey (THAOS) in Japan. Amyloid, 2019. 26(sup1): p. 61-62.; Damy, T., et al., Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyret in Amyloidosis Outcomes Survey (THAOS). Eur Heart J, 2019.; Plante-Bordeneuve, V., et al., The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin, 2013. 29(1): p. 77-84.; Coelho, T., M.S. Maurer, and O.B. Suhr, THAOS — The Transthyretin Amyloidosis Outcomes Survey: init ial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin, 2013. 29(1): p. 63-76.; Real de Asua , D., et al., Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol, 2014. 6: p. 369-77.; Leone, O., et al., Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur Heart J, 2004 . 25(14): p. 1237-41.; Rocken, C., et al., Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Ci rculation, 2002. 106(16): p. 2091-7.; Neben-Wittich, M.A., et al., Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primar y amyloidosis. Am J Med, 2005. 118(11): p. 1287.; Резник, Е.В., Г.Е. Гендлин, Г.И. Сторожаков, Эхокардиография в практике кардиолога. Москва, Пр актика; 2013. 212 с.; Fonta na, M., et al., Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev, 2015. 20(2): p. 133-44.; Kwong, R.Y., et al., Characterization of Cardiac Amyloidosis by Atrial Late Gadolinium Enhancement Using Contrast-Enhanced Cardiac Magnetic Resonance Imaging and Correlation With Left Atrial Conduit and Contractile Function. Am J Cardiol, 2015. 116(4): p. 622-9.; Banypersad, S.M., et al., T1 mapping and survival in systemic lightchain amylo idosis. Eur Heart J, 2015. 36(4): p. 244-51.; Strouse, C., et al., Approach to a patient with cardiac amyloidosis. J Geriatr Cardiol, 2019. 16(7): p. 567-574.; Park, G.Y., et al., Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Dise ases. Int J Mol Sci, 2019. 20(12).; Caobelli, F., et al., Quantitative (99m)Tc-DPD SPECT/CT in patients with suspected ATTR c ardiac amyloidosis: Feasibility and correlation with visual scores. J Nucl Cardiol, 2019.; Yamamoto, H. and T. Yok ochi, Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail, 2019. 6(6): p. 1128-1139.; Gopal, D.M., F. L. Ruberg, and O.K. Siddiqi, Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis. Curr Heart Fail Rep, 2019. 16(5): p. 180-188.; Fajardo, J., et al., Clinical pat hway to screen for cardiac amyloidosis in heart failure with preserved ejection fraction. Amyloid, 2019. 26(sup1): p. 166-167.; Manolis, A.S., et al., Cardiac amyloidosis: An underdiagnosed/underappreciated disease. Eur J Intern Med, 2019. 67: p. 1-13.; Gertz, M.A., et al., Advances in the treatment of her editary transthyretin amyloidosis: A review. Brain Behav, 2019. 9(9): p. e01371.; Maurer, M.S., et al., Tafamidis Treatment for Patients with Transthyretin Amylo id Cardiomyopathy. N Engl J Med, 2018. 379(11): p. 1007-1016.; Wechalekar, A.D., et al., Guidelines on the management of AL am yloidosis. Br J Haematol, 2015. 168(2): p. 186-206.; Dember, L.M., et al., Eprodisate for the treatment of renal disease in AA amyloido sis. N Engl J Med, 2007. 356(23): p. 2349-60.; Zhu, H., J. Yu, and M.S. Kindy, Inhibition of amyloidosis using lowmolecular-weight heparins. Mol Med, 2001. 7(8): p. 517-22.; van der Hilst, J.C., et al., Lovastatin inhibits formation of AA amyloid. J Leukoc Biol, 2008. 83(5): p. 1295-9.; Gillmore, J.D., et al., Sustained pharmacological depletion of serum amyloid P component in patien ts with systemic amyloidosis. Br J Haematol, 2010. 148(5): p. 760-7.; Kluve-Beckerman, B., et al., Antisense oligonucleotide sup pression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis. Amyloid, 2011. 18(3): p. 136-46.; Kennel, S.J., et al., Phagocyte depletion inhibits AA amyloid accumulation in AEF-induced huIL-6 transgenic mice. Amyloid, 2014. 21(1): p. 45-53.; Oerlemans, M., et al., Cardiac amyloidosis: the need for early diagnosis. Neth Heart J, 2019. 27(11): p. 525-536.; Sucker, C., et al., Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis, 2006. 47(6): p. 947-55.; Ishiguro, K., et al., Elevation of Plasmin-alpha2-plasmin Inhibitor Complex Predicts the Diagnos is of Systemic AL Amyloidosis in Patients with Monoclonal Protein. Intern Med, 2018. 57(6): p. 783-788.; https://www.medarhive.ru/jour/article/view/1106

Διαθεσιμότητα: https://www.medarhive.ru/jour/article/view/1106
https://doi.org/10.20514/2226-6704-2020-10-6-430-457

View record from BASE

11

Academic Journal

NEW EMPHASES ON THE STUDY OF THE PATHOGENESIS OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: FOCUS ON INFLAMMATORY MARKERS

Συγγραφείς: O. M. Drapkina, L. O. Palatkina

Πηγή: Рациональная фармакотерапия в кардиологии, Vol 10, Iss 3, Pp 317-321 (2015)

Θεματικοί όροι: хроническая сердечная недостаточность, хроническая сердечная недостаточность с сохраненной фракцией выброса, воспаление, цитокины, GDF-15, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

Περιγραφή αρχείου: electronic resource

Relation: http://www.rpcardio.ru/jour/article/view/258; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653

Σύνδεσμος πρόσβασης: https://doaj.org/article/81bca212ea0e4863a89b5b9615d18c58

View record in DOAJ Full Text Finder

12

Academic Journal

NEW EMPHASES ON THE STUDY OF THE PATHOGENESIS OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: FOCUS ON INFLAMMATORY MARKERS

Συγγραφείς: O. M. Drapkina, L. O. Palatkina

Πηγή: Рациональная фармакотерапия в кардиологии, Vol 10, Iss 3, Pp 317-321 (2015)

Θεματικοί όροι: цитокины, RM1-950, 02 engineering and technology, cytokines, хроническая сердечная недостаточность, chronic heart failure, GDF-15, 3. Good health, 03 medical and health sciences, хроническая сердечная недостаточность с сохраненной фракцией выброса, 0302 clinical medicine, inflammation, 13. Climate action, RC666-701, 0202 electrical engineering, electronic engineering, information engineering, Diseases of the circulatory (Cardiovascular) system, Therapeutics. Pharmacology, gdf-15, воспаление, chronic heart failure with preserved ejection fraction

Σύνδεσμος πρόσβασης: https://www.rpcardio.com/jour/article/download/258/269
https://doaj.org/article/81bca212ea0e4863a89b5b9615d18c58
https://doaj.org/article/13fd6fdfdcd64be19ac93f488f3821ff
https://www.rpcardio.com/jour/article/view/258/269
https://core.ac.uk/display/87816561
https://doaj.org/article/13fd6fdfdcd64be19ac93f488f3821ff
https://www.rpcardio.com/jour/article/download/258/269

View record at OpenAIRE Full Text Finder

13

Academic Journal

Late ventricular potentials in chronic heart failure patients with preserved ejection fraction ; Поздние потенциалы желудочков у пациентов с хронической сердечной недостаточностью с сохраненной фракцией выброса

Συγγραφείς: Dushina A.G., Libis R.A.

Πηγή: Almanac of Clinical Medicine; Vol 45, No 3 (2017); 247-253 ; Альманах клинической медицины; Vol 45, No 3 (2017); 247-253 ; 2587-9294 ; 2072-0505 ; 10.18786/2072-0505-2017-45-3

Θεματικοί όροι: late ventricular potentials, chronic heart failure with preserved ejection fraction, поздние потенциалы желудочков, хроническая сердечная недостаточность с сохраненной фракцией выброса

Περιγραφή αρχείου: application/pdf

Relation: https://almclinmed.ru/jour/article/view/546/550; https://almclinmed.ru/jour/article/downloadSuppFile/546/1296; https://almclinmed.ru/jour/article/downloadSuppFile/546/1297; https://almclinmed.ru/jour/article/downloadSuppFile/546/1298; https://almclinmed.ru/jour/article/view/546

Διαθεσιμότητα: https://almclinmed.ru/jour/article/view/546
https://doi.org/10.18786/2072-0505-2017-45-3-247-253

View record from BASE

14

Academic Journal